paclitaxel 6 mg/ml concentrate for solution for infusion
fresenius kabi limited - paclitaxel - concentrate for solution for infusion - 6 milligram(s)/millilitre - taxanes; paclitaxel
docefim concentrate for soln for inf 20 mg/ml
alfred e tiefenbacher (gmbh & co. kg) - docetaxel anhydrous - concentrate for soln for inf - 20 mg/ml
docefim concentrate for soln for inf 80 10 milligram
alfred e tiefenbacher (gmbh & co. kg) - docetaxel anhydrous - concentrate for soln for inf - 80 10 milligram
docirena concentrate for soln for inf 20 mg/ml
fresenius kabi limited - docetaxel anhydrous - concentrate for soln for inf - 20 mg/ml
docirena concentrate for soln for inf 80 10 milligram
fresenius kabi limited - docetaxel anhydrous - concentrate for soln for inf - 80 10 milligram
docetaxel 80 10 milligram concentrate for soln for inf
seacross pharmaceuticals - docetaxel anhydrous - concentrate for soln for inf - 80 10 milligram
docirena 80 10 milligram concentrate for soln for inf
fresenius kabi limited - docetaxel anhydrous - concentrate for soln for inf - 80 10 milligram
docirena 20 mg/ml concentrate for soln for inf
fresenius kabi limited - docetaxel anhydrous - concentrate for soln for inf - 20 mg/ml
bioestrovet 0.250 mg/ml solution for injection for cattle
vetoquinol uk limited - cloprostenol - solution for injection - 0.250 milligram(s)/millilitre - cloprostenol - cattle - hormone
paclitaxel kabi paclitaxel 300 mg/50 ml concentrated injection vial
fresenius kabi australia pty ltd - paclitaxel, quantity: 300 mg - injection, concentrated - excipient ingredients: ethanol; citric acid; peg-35 castor oil - primary treatment of ovarian cancer in combination with a platinum agent. treatment of metastatic carcinoma of the ovary after failure of standard therapy. treatment of metastatic carcinoma of the breast after failure of standard therapy. adjuvant treatment of node-positive breast cancer administered sequentially to doxorubicin and cyclophosphamide. treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that over-express her-2 and who have not received previous chemotherapy for their metastatic disease. in combination with gemcitabine (gemzar), the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. treatment of non-small cell lung cancer (nsclc).